Small Cap Feast

Small Cap Feast – 17 January 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 916

Total number of AIM Companies trading: 846*
* As at 15 January 2019

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): 89*

Total number of NEX Growth Market Companies trading: 87*
* As at 15 January 2019

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): 139*

Total number of Standard List Companies trading: 130*
* As at 15 January 2019

Dish of the Day:

No Joiners Today

Off the Menu:

Bioquell has left the main  market (premium)  following a £140.5m takeover by  Ecolab.

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

Main Market (Specialist Funds)

The Global Sustainability Trust -aiming for attractive risk-adjusted returns by investing primarily in private market investments that are expected to have a positive environmental and social impact raising c.£200m. Due 31 Jan 2019.

Main Market (Standard)

Dev Clever Hldgs—Raising up to £700k gross.  The Group has invested over £600,000 in the last five years in developing proprietary software platforms and immersive frameworks to reshape the way its clients engage, acquire and retain their customers and employees through experience, rewards and incentives.  Mkt cap c. £3.7m


Circassia Pharma (CIR.L) – specialty pharmaceutical company focused on respiratory disease transferring from the Main Market. No funds being raised. Due 4 Feb.

Greenfields Petroleum (TSX-V:GNF)  production focused company with operated assets in Azerbaijan seeking AIM dual listing including $60m private placement. Mkt cap $12.6m CAD. Expected late January 2019.

Breakfast Buffet

Oracle Power (ORCP.L) 0.53p £5.14m

The UK energy developer of a combined lignite coal mine and mine mouth power plant located in the Thar desert in the south-eastern Sindh Province of Pakistan, today provides an update on recent operational and macro developments. 

Block VI maintained as Priority Project in 8th Joint Cooperation Committee  meeting;

China Pakistan Economic Corridor (“CPEC”) approve Oracle proposed expansion to 700MW;

Consortium partnership change noted in CPEC.


Iofina (IOF.L) 15p £17.45m

“The exploration and production of iodine and halogen-based specialty chemical derivatives, updated the market on an exceptional year for the Group, in which it produced record volumes of crystalline iodine and executed on the Group’s commitment to growth and increased profitability.”

H2 2018 324.7 metric tonnes (‘MT’) a 21% increase YOY (H2 2017: 267.5MT)

Full year production in 2018 of 588.8MT a YOY increase of 17% (2017: 503MT)

H1 2019 production currently forecast at 310-330 MT of crystalline iodine.

Iofina Chemical continues to trade strongly in both iodine and non-iodine products.


Fox Marble Holdings (FOX.L) 7.88p £15.8m

Fox Marble announces the start of commercial extraction of Alexandrian Blue from the Prilep quarry in Northern Macedonia.  Alexandrian Blue has dense blue grey banding with smaller bands of white which produce a marked blue tone and is akin to the highly desirable Zebrino marble from Northern Italy.

Fox Marble sold, and received payment for, 441 tonnes of Alexandrian Blue extracted in December 2018 to a single customer. Following this order, the Company entered into a sales agreement with this customer to purchase Alexandrian Blue with an expected value over 1m over the next  twelve  months. 


Ten Entertainment (TEG.L) 220p £143m

FYDec18 update from UK based operator of 43 family entertainment centres.

The Group performed well during the full-year, achieving total sales growth of 7.5%to £76.35m.

Like-for-like sales growth was 2.7%, which demonstrates the strength of consumer demand, despite the significant impact of unprecedented hot weather during the summer period. 

The Group has made further progress with the expansion of the estate with the acquisition of four sites, which was at the upper end of the acquisitions forecast. All four sites have been extensively refurbished during FY18 and are expected to perform in line with our expectations during FY19.  In addition, one under-performing site was disposed of during the year.


XL Media (XLM.L) 71.9p £162.8m

The “provider of digital performance marketing services, provided an update for the year ended 31 Dec 2018.

XLMedia confirms that trading in the second half of 2018 continued to strengthen with the Group proactively focusing on higher margin business.  As a result of this overall margin improvement, the Group expects to report EBITDA in line with current market expectations, achieved against lower revenue base of approximately $118m. The Company has a material cash balance and continues to generate strong cash flows from operations.

The Company is focused on growing the higher margin publishing division within its key strategic verticals: Gaming (including the newly re-regulated US Gambling market), and Personal Finance. The Company looks forward to providing a more detailed update to the market as part of the full year results announcement.


Taptica (TAP.L) 179.5p £125.1m

echnologies for performance-based mobile marketing and brand advertising, reported that it closed the financial year to 31 Dec 2018 in line with management expectations.

As at 31 Dec 2018, the Company had net cash of $54.4m, which was following a $2.7m dividend paid to shareholders on 20 Nov 2018 (30 June 2018: $42.1m ).

Further to the announcement made on 3 Jan 2019, the Company can confirm that it remains in discussions with a potential acquisition target. Further announcements will be made in due course and there can be no certainty that any transaction will follow or regarding the terms of any such transaction.

FYDec18E rev $220m and PBT $22.55m. PE c.5x.


Frontier Smart Tech (FST.L) 33.5p £12.22m

Unaudited trading update for the year ended 31 Dec 2018  from the Pioneer in technologies for Digital Radio and Smart Audio devices

The Group expects to report a much improved second half and a FY 2018 financial performance broadly in line with current market expectations. Revenue for the financial year is expected to be not less than $41.m and EBITDA is anticipated to be c.$1.4m.

Frontier’s priorities are to:

Maximise Digital Radio cashflows

Control R&D expenditure and leverage ecosystem relationships in Smart Audio

Establish a Licensing business, which exploits the Group’s multi-ecosystem software and cloud assets, to address the opportunities in Smart Audio and Smart IoT


Synairgen (SNG.L) 16.1p £14.77m

Pharmaxis has reported receipt of all data for the LOXL2 inhibitor candidates in three-month toxicity studies.  These data complete the overall package required for Pharmaxis’ partnering discussions.

In Nov 2018 Pharmaxis announced the successful completion of the Phase I single and multiple ascending dose trials of their two LOXL2 inhibitor compounds.  Data from the Phase I trials support once daily oral dosing and demonstrated best-in-class inhibition of the LOXL2 enzyme. Together with preclinical data in models of fibrosis, this package shows the potential of these compounds to target diseases associated with LOXL2 such as Non‐alcoholic Steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF)



Arena Events (ARE.L) 38.2p £88.1m

The Board expects revenues for the year ended 31 Dec 2018 to be in-line with expectations but as a result of the increased costs in the UK division in the fourth quarter, the Board now expects Adjusted EBITDA for the year ended 31 Dec 2018 to be in the range of £12m to £12.5 m. Notwithstanding, the Group still expects to report approximately 25% growth in Adjusted EPS for 2018 over the prior year. The Group enters 2019 with a number of new contracted projects and a full year contribution from acquisitions which is expected to result in a material increase in earnings for the year to 31 Dec 2019.  However, as a result of the impact of the UK operational issues, wider economic uncertainty and a prudent view on the timing of a number of large potential one off contracts, the Board is taking a more conservative outlook for 2019.

Serabi Gold (SRB.L) 37p £19.15m

The Brazilian focused gold mining and development company, provided the results and a review of its fourth quarter operational and exploration activities in the Tapajos region of Para State, Northern Brazil.  Fourth quarter gold production of 10,256 ounces of gold represents record quarterly production for Serabi. Annual gold production totalling 37,108 ounces is an improvement on 2017 production. Highest level of mined tonnage for 2018 achieved in fourth quarter with a total of 44,257 tonnes at 7.45 g/t of gold.  2,460 metres of horizontal development completed during the quarter, giving a total of 10,371m for the year.

A series of discrete “apparent conductivity” anomalies have been delineated by the analysis of the airborne magnetic and electromagnetic survey flown during the third quarter of 2018.  These anomalies are indicative of probable sulphide bodies which the Company hopes will be gold bearing.


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.